Nielsen Sebastian W, Lindberg Sanne, Ruhlmann Christina Halgaard Bruvik, Eckhoff Lise, Herrstedt Jørn
Department of Clinical Oncology and Palliative Care, Zealand University Hospital, 4000 Roskilde, Denmark.
Department of Clinical Research, University of Southern Denmark, 5000 Odense C, Denmark.
J Clin Med. 2022 Mar 27;11(7):1862. doi: 10.3390/jcm11071862.
(1) The study evaluated correlations between multi-frequency vibrometry (MF-V) and the measure of chemotherapy-induced peripheral neuropathy developed by the European Organization for the Research and Treatment of Cancer (CIPN18). (2) Patients with cancer scheduled to undergo treatment with capecitabine and oxaliplatin (CAPOX) or carboplatin and paclitaxel (Carbo-Tax) were recruited in a prospective, observational study with MF-V and the CIPN18 from baseline to one year after end of treatment. (3) The study recruited 31 evaluable patients. All MF-V measurements correlated significantly with the CIPN18 scores (r = 0.25−0.48, p > 0.003), with a low frequency (32 Hz) from metatarsals showing the best correlation coefficients (0.059 Z-score per CIPN18 point change, r = 0.48, CI-95 = [0.32; 0.60], p > 0.0001). The largest change in MF-V scores from baseline was seen in low-frequency VPTs taken from metatarsals at 8 Hz three months after end of treatment (from −0.26, CI-95 [−0.85, 0.38] to 1.15, CI-95 [0.53, 1.84]) for patients treated with oxaliplatin and at 32 Hz one year after end of treatment (from 0.09, CI-95 [−0.56, 0.77] to 0.88, CI-95 [0.34, 1.47]) for patients treated with paclitaxel. (4) Low-frequency vibration perception thresholds (8 and 32 Hz) correlated better with CIPN18 scores than high-frequency ones (128 and 250 Hz). If validated, this finding will advance CIPN pathophysiological understanding and inform the development of assessment methods.
(1) 本研究评估了多频振动测量法（MF-V）与欧洲癌症研究与治疗组织制定的化疗引起的周围神经病变测量方法（CIPN18）之间的相关性。(2) 计划接受卡培他滨和奥沙利铂（CAPOX）或卡铂和紫杉醇（Carbo-Tax）治疗的癌症患者被纳入一项前瞻性观察性研究，从基线到治疗结束后一年采用MF-V和CIPN18进行评估。(3) 该研究招募了31名可评估患者。所有MF-V测量值均与CIPN18评分显著相关（r = 0.25−0.48，p > 0.003），其中来自跖骨的低频（32 Hz）显示出最佳相关系数（每CIPN18评分点变化0.059 Z评分，r = 0.48，CI-95 = [0.32; 0.60]，p > 0.0001）。治疗结束后三个月，接受奥沙利铂治疗的患者在8 Hz时从跖骨获取的低频振动觉阈值（VPT）的MF-V评分自基线的最大变化（从−0.26，CI-95 [−0.85, 0.38] 至1.15，CI-95 [0.53, 1.84]）；接受紫杉醇治疗的患者在治疗结束后一年在32 Hz时（从0.09，CI-95 [−0.56, 0.77] 至0.88，CI-95 [0.34, 1.47]）。(4) 低频振动觉阈值（8 Hz和32 Hz）与CIPN18评分的相关性优于高频（128 Hz和250 Hz）。如果得到验证，这一发现将推进对CIPN病理生理学的理解，并为评估方法的开发提供信息。
